Lasa Supergenerics Limited (BOM:540702)

India flag India · Delayed Price · Currency is INR
7.60
-0.01 (-0.13%)
At close: Apr 13, 2026
Market Cap381.77M -61.3%
Revenue (ttm)669.61M -47.8%
Net Income-442.17M
EPS-9.07
Shares Outn/a
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume2,253
Average Volume16,206
Open7.62
Previous Close7.61
Day's Range7.60 - 7.69
52-Week Range5.65 - 19.65
Betan/a
RSI55.62
Earnings DateMay 26, 2026

About Lasa Supergenerics

Lasa Supergenerics Limited engages in the research, manufacture, and marketing of animal and human healthcare products in India. It offers API bulk drug products comprising fenbendazole, toldimphos sodium, cyromazine, albendazole, ricobendazole, triciabendazole, oxfendazole, closantel base, closantel sodium dihydrate BP, nitroxynil, rafoxanide, oxyclozanide, ornidazole, halquinol, and 2,6-diiodo-4-nitrophenol; and other API products. The company also provides animal feed ingredients, including calcium iodate; and reagents for therapeutic use, s... [Read more]

Industry Medicinal Chemicals and Botanical Products
Founded 2016
Employees 66
Stock Exchange Bombay Stock Exchange
Ticker Symbol 540702
Full Company Profile

Financial Performance

In fiscal year 2025, Lasa Supergenerics's revenue was 1.47 billion, an increase of 41.20% compared to the previous year's 1.04 billion. Losses were -147.57 million, -32.09% less than in 2024.

Financial Statements